Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what data the Department holds on the proportion of patients with restless legs syndrome alone, compared with patients with restless legs syndrome and attention deficit hyperactivity disorder, autism or bipolar disorder, who develop new impulse control disorders or worsening pre-existing impulse control traits after dopamine agonist exposure; and whether similar data are available for Parkinson’s disease patients with those co-morbidities.

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.